ALIM Stock - Alimera Sciences Inc.

ALIM Stock Chart

ALIM Profile

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic pharmaceuticals in the United States and internationally. Its primary product is ILUVIEN, an intravitreal implant designed to treat diabetic macular edema (DME), a retinal disease affecting people with diabetes that can lead to severe vision loss and blindness. ILUVIEN is also used to prevent relapse in patients with recurrent non-infectious uveitis affecting the posterior segment of the eye.

The company distributes its products to physician offices, pharmacies, and hospitals through both direct sales and distributors. Alimera Sciences has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop and market insert technology for delivering other corticosteroids to the back of the eye, targeting the treatment and prevention of various eye diseases, including diabetic macular edema.

Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences continues to expand its presence in the ophthalmic pharmaceutical market. The company aims to provide innovative solutions to improve the quality of life for individuals suffering from severe eye diseases.

ALIM Revenue Chart

ALIM Earnings

Analyst Ratings